查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1887154

治療性白蛋白市場規模、佔有率、成長及全球產業分析：按類型、應用和地區劃分的洞察，以及2024年至2032年的預測

Therapeutic Albumin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 186 Pages | 商品交期: 請詢問到貨日

價格

治療性白蛋白市場成長因子

受嚴重疾病發病率上升和急診護理需求增加的推動，全球治療性白蛋白市場正經歷著穩定且持續的增長。根據最新的產業評估，預計2024年全球市場規模將達到44.2億美元，2025年將成長至47.1億美元，到2032年將達到75.5億美元。亞太地區預計將在2024年引領市場，佔全球收入的54.52%，這主要得益於該地區疾病的高發生率和血漿衍生產品的廣泛應用。

治療性白蛋白源自人類血漿，用於治療低血容、燒傷、低白蛋白血症、急性肝衰竭、休克和手術併發症等疾病。其主要功能包括維持滲透壓和運輸必需分子，因此對於維持體液平衡和支持重症患者復原至關重要。在全球慢性病日益增多的背景下，醫療保健系統擴大採用基於白蛋白的療法，從而推動了市場的持續成長。

市場概覽

  • 2024年市場規模：44.2億美元
  • 2025年市場規模：47.1億美元
  • 2032年市場規模：75.5億美元
  • 主要地區（2024年）：亞太地區 -54.52%
  • 主要適應症：由於全球燒傷發生率高，燒傷治療仍是一個主要細分市場。

市場驅動因素

慢性病的增加是推動市場擴張的最重要因素之一。全球數百萬患者患有腎臟疾病、肝衰竭以及促使低白蛋白血症的疾病，迫使醫院依賴白蛋白療法。 2024年4月，美國疾病管制與預防中心 (CDC) 報告稱，美國有600萬腎臟病患者和450萬慢性肝病患者，這推動了急診和重症監護環境中對白蛋白的需求。

燒傷仍是影響白蛋白醫療需求的重要因素。根據美國燒傷協會統計，2023年有32,540例嚴重燒傷病例需要住院治療，其中數千例涉及創傷相關併發症。白蛋白有助於恢復體液平衡，在這些病例中至關重要，從而促進了燒傷治療市場的成長。

市場限制因子

由於依賴人類血漿，該市場面臨供應鏈和生產方面的挑戰。自願捐血的短缺阻礙了白蛋白的穩定供應。 2024年1月，美國紅十字會宣布捐血量下降了40%，促使用於提取白蛋白的血漿供應緊張。這種波動限制了製造商滿足不斷增長的需求的能力，從而促使價格上漲和全球供應緊張。

市場機會

重組白蛋白技術正在為未來的成長創造新的機會。白蛋白在再生醫學、組織工程和細胞療法中的應用日益廣泛，正在擴大其臨床應用範圍。 2023年3月，Albumedix與HeartSeed合作，將重組人類白蛋白（Recombumin）整合到心臟再生醫學中，展示了其在傳統重症監護之外的更廣泛應用。

植物源性白蛋白的進步，例如Healthgen BIoTechnology於2025年開發的稻米源性HSA，為解決供應短缺和污染風險提供了方案。這些創新增強了可擴展性，並有助於長期市場穩定。

市場趨勢

重組白蛋白產品研發的臨床試驗不斷增加，正在重塑產業格局。各公司正利用生物技術驅動的生產方式來解決供體來源白蛋白供應不足的問題。 2024年8月，Silpa Medicare完成了其重組酵母源性白蛋白 "sRbumin" 的I期臨床試驗，凸顯了下一代治療性白蛋白產品研發的快速進展。這些進步提高了產品的均一性、安全性和全球供應。

市場區隔概覽

依原料劃分

2024年，人血白蛋白憑藉其在醫院的廣泛應用和廣泛的臨床用途，佔了市場主導地位。持續獲得批准的產品，例如 Grifols 的 ALBUTEIN FlexBag，進一步鞏固了該細分市場的領先地位。

依適應症劃分

根據世界衛生組織 (WHO) 的追蹤數據，全球每年有 660 萬例燒傷病例，燒傷治療領域持續佔主導地位。在印度，每年燒傷病例數達到 600 萬至 700 萬例，對該地區的需求貢獻巨大。

依通路劃分

由於白蛋白治療需要在醫院進行，因此醫院藥局是主要的通路。在美國，約有 170 家醫院已將白蛋白引入胸腔外科手術，進一步鞏固了其主導地位。

區域展望

亞太地區

亞太地區預計2024年市場規模將達24.1億美元，引領全球市場。這主要得益於慢性病高發生、燒傷病例不斷增加以及眾多主要生產商的存在。中國國家食品藥物管理局（NIFDC）批准了一種新的人血白蛋白產品，進一步鞏固了該地區的供應基礎。

北美

成長主要得益於血漿採集能力的提升及先進生產設施的完善。策略性收購，例如Grifols收購Prometic Plasma Resources，也為擴大供應提供了支援。

歐洲

歐洲憑藉強勁的研發實力，佔第二大市場。 Grifols的Preciosa III期臨床試驗（2024年）證實了熊果素能夠提高患者的存活率，從而促進了其臨床應用。

拉丁美洲、中東和非洲

成長的驅動因素包括慢性病發病率上升、血漿採集網絡擴大以及血漿療法監管法規的演變。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：主要發現

  • 2024年主要國家和地區主要疾病盛行率
  • rHSA產品參數概述
  • 主要公司新產品發布
  • 主要公司產品線分析
  • 主要產業趨勢（併購、合作等）
  • COVID-19對全球治療市場的影響白蛋白市場

第五章：全球治療性白蛋白市場分析、洞察與預測（2019-2032）

  • 市場分析、洞察與預測 - 按來源
    • 人源性
    • 其他
  • 市場分析、洞察與預測 - 按適應症
    • 低血容
    • 低白蛋白血症
    • 燒傷
    • 其他
  • 市場分析、洞察與預測 - 按分銷管道
    • 醫院藥房
    • 零售藥房
    • 線上藥房
  • 市場分析、洞察與預測 - 按地區
    • 北美美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美治療性白蛋白市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲治療性白蛋白市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 歐洲其他地區

第八章 亞太地區治療性白蛋白市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：拉丁美洲治療性白蛋白市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章：中東與非洲治療性白蛋白市場分析、洞察與預測（2019-2032）

  • 依國家/地區
    • 海灣合作委員會 (GCC)
    • 南非
    • 中東和非洲其他地區

第十一章 競爭分析

  • 全球市佔率分析 (2024)
  • 公司簡介
    • 武田藥品工業株式會社
    • CSL
    • 格里福爾斯公司
    • 奧克塔製藥股份公司
    • 凱德瑞恩股份公司
    • BIoTest股份公司
    • LFB（法國）
    • 中國生物製品控股股份有限公司
    • 百特
Product Code: FBI112839

Growth Factors of therapeutic albumin Market

The global therapeutic albumin market is experiencing steady and sustained expansion, supported by rising incidences of critical medical conditions and increased demand in emergency care. According to the latest industry assessment, the global market was valued at USD 4.42 billion in 2024, is projected to grow to USD 4.71 billion in 2025, and reach USD 7.55 billion by 2032. The Asia Pacific region dominated the market landscape in 2024, capturing 54.52% of global revenue due to high disease prevalence and expanding plasma-based product utilization.

Therapeutic albumin is derived from human plasma and used to treat conditions such as hypovolemia, burns, hypoalbuminemia, acute liver failure, shock, and surgical complications. Its primary functions include maintaining oncotic pressure and transporting essential molecules, making it crucial for managing fluid imbalance and supporting patient recovery in severe illnesses. With chronic diseases rising globally, healthcare systems continue to expand their use of albumin-based therapies, driving consistent market growth.

Market Snapshot

  • 2024 Market Size: USD 4.42 billion
  • 2025 Market Size: USD 4.71 billion
  • 2032 Market Size: USD 7.55 billion
  • Dominant Region (2024): Asia Pacific - 54.52%
  • Key Indication: Burn treatment remains dominant due to high global burn incidence.

Market Drivers

Increasing chronic disease burden is one of the most influential forces behind the market's expansion. Millions of patients globally suffer from kidney disease, liver failure, and conditions leading to hypoalbuminemia, driving hospitals to rely on albumin therapy. In April 2024, the CDC reported 6.0 million kidney disease cases and 4.5 million chronic liver disease cases in the U.S., strengthening demand for albumin in acute and critical care.

Burn injuries continue to significantly impact medical demand for albumin. As per the American Burn Association, 32,540 severe burn cases required inpatient hospitalization in 2023, including thousands with trauma-related complications. Albumin, which aids fluid balance restoration, is indispensable in such cases, contributing to the growth of the burn indication segment.

Market Restraints

The market faces supply chain and production challenges due to dependence on human-derived plasma. Shortages in voluntary blood donation hinder consistent albumin availability. In January 2024, the American Red Cross announced a 40% decline in blood donations, tightening plasma supply for albumin extraction. Such fluctuations limit manufacturers' ability to meet rising demand and contribute to price increases and global supply constraints.

Market Opportunities

Recombinant albumin technology is creating new opportunities for future growth. The rising adoption of albumin in regenerative medicine, tissue engineering, and cell therapy is broadening its clinical utility. In March 2023, Albumedix partnered with Heartseed to integrate recombinant human albumin (Recombumin) into cardiac regenerative therapy, demonstrating expanding applications beyond traditional critical care.

Advancements in plant-derived albumin, such as rice-based HSA developed by Healthgen Biotechnology in 2025, offer solutions to supply shortages and contamination risks. These innovations enhance scalability and support long-term market stability.

Market Trends

Increasing clinical trials to develop recombinant albumin products are shaping industry trends. Companies are addressing supply limitations of donor-derived albumin through biotechnology-led production. In August 2024, Shilpa Medicare completed Phase 1 trials of sRbumin, a recombinant yeast-derived albumin, highlighting rapid progress toward next-generation therapeutic albumin products. Such advancements enhance consistency, safety, and global availability.

Segmentation Overview

By Source

The human-derived albumin segment dominated in 2024 due to widespread adoption in hospitals and broad clinical applicability. Continuous approvals-such as Grifols' ALBUTEIN FlexBag-strengthen segment leadership.

By Indication

The burn segment remains dominant, supported by 6.6 million thermal burn cases annually worldwide as tracked by WHO. Rising burn incidence in India, reaching 6-7 million cases per year, contributes significantly to regional demand.

By Distribution Channel

Hospital pharmacies lead due to the intensive, hospital-based nature of albumin treatments. Albumin usage in thoracic surgeries, adopted by nearly 170 U.S. hospitals, reinforces this dominance.

Regional Outlook

Asia Pacific

Valued at USD 2.41 billion in 2024, Asia Pacific leads the global market due to high chronic disease prevalence, increasing burn injuries, and the presence of major manufacturers. China's NIFDC approval for new human albumin products is strengthening regional supply.

North America

Growth is driven by rising plasma collection capabilities and advanced production facilities. Strategic acquisitions-such as Grifols' purchase of Prometic Plasma Resources-support supply expansion.

Europe

Europe holds the second-largest share, driven by strong R&D efforts. Grifols' PRECIOSA Phase 3 trial in 2024 demonstrated survival benefits of Albutein, boosting clinical adoption.

Latin America & Middle East/Africa

Growth is supported by rising chronic disease rates, expanding plasma collection networks, and regulatory advancements for plasma therapeutics.

Conclusion

The therapeutic albumin market is poised for solid expansion-growing from USD 4.42 billion in 2024 to USD 4.71 billion in 2025, and ultimately reaching USD 7.55 billion by 2032. Rising chronic diseases, burn incidences, biotechnology innovations, and expanding regenerative medicine applications will drive the market's future trajectory.

Segmentation By Source

  • Human
  • Others

By Indication

  • Hypovolemia
  • Hypoalbuminemia
  • Burn
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (By Source, Indication, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Source, Indication, Distribution Channel, and Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Source, Indication, Distribution Channel, and Country/Sub-region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Source, Indication, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Source, Indication, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Disorders: by Key Countries/Sub-regions, 2024
  • 4.2. Overview: rHSA Product Parameters
  • 4.3. New Product Launches, By Key Players
  • 4.4. Pipeline Analysis, By Key Players
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.6. Impact of COVID-19 on the Global Therapeutic Albumin Market

5. Global Therapeutic Albumin Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Source
    • 5.1.1. Human
    • 5.1.2. Others
  • 5.2. Market Analysis, Insights and Forecast - By Indication
    • 5.2.1. Hypovolemia
    • 5.2.2. Hypoalbuminemia
    • 5.2.3. Burn
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Retail Pharmacies
    • 5.3.3. Online Pharmacies
  • 5.4. Market Analysis, Insights and Forecast - Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Therapeutic Albumin Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Source
    • 6.1.1. Human
    • 6.1.2. Others
  • 6.2. Market Analysis, Insights and Forecast - By Indication
    • 6.2.1. Hypovolemia
    • 6.2.2. Hypoalbuminemia
    • 6.2.3. Burn
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Retail Pharmacies
    • 6.3.3. Online Pharmacies
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Therapeutic Albumin Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Source
    • 7.1.1. Human
    • 7.1.2. Others
  • 7.2. Market Analysis, Insights and Forecast - By Indication
    • 7.2.1. Hypovolemia
    • 7.2.2. Hypoalbuminemia
    • 7.2.3. Burn
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Retail Pharmacies
    • 7.3.3. Online Pharmacies
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. Germany
    • 7.4.2. U.K.
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Therapeutic Albumin Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Source
    • 8.1.1. Human
    • 8.1.2. Others
  • 8.2. Market Analysis, Insights and Forecast - By Indication
    • 8.2.1. Hypovolemia
    • 8.2.2. Hypoalbuminemia
    • 8.2.3. Burn
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Therapeutic Albumin Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Source
    • 9.1.1. Human
    • 9.1.2. Others
  • 9.2. Market Analysis, Insights and Forecast - By Indication
    • 9.2.1. Hypovolemia
    • 9.2.2. Hypoalbuminemia
    • 9.2.3. Burn
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Therapeutic Albumin Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Source
    • 10.1.1. Human
    • 10.1.2. Others
  • 10.2. Market Analysis, Insights and Forecast - By Indication
    • 10.2.1. Hypovolemia
    • 10.2.2. Hypoalbuminemia
    • 10.2.3. Burn
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Retail Pharmacies
    • 10.3.3. Online Pharmacies
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. Takeda Pharmaceutical Company Limited.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. CSL
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Grifols, S.A.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Octapharma AG
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Kedrion S.p.A.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Biotest AG
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. LFB (France)
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. China Biologic Products Holdings, Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Baxter
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Therapeutic Albumin Market Revenue (USD billion) Forecast, by Source, 2019-2032
  • Table 2: Global Therapeutic Albumin Market Revenue (USD billion) Forecast, by Indication, 2019-2032
  • Table 3: Global Therapeutic Albumin Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 4: Global Therapeutic Albumin Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 5: North America Therapeutic Albumin Market Revenue (USD billion) Forecast, by Source, 2019-2032
  • Table 6: North America Therapeutic Albumin Market Revenue (USD billion) Forecast, by Indication, 2019-2032
  • Table 7: North America Therapeutic Albumin Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 8: North America Therapeutic Albumin Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 9: Europe Therapeutic Albumin Market Revenue (USD billion) Forecast, by Source, 2019-2032
  • Table 10: Europe Therapeutic Albumin Market Revenue (USD billion) Forecast, by Indication, 2019-2032
  • Table 11: Europe Therapeutic Albumin Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 12: Europe Therapeutic Albumin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 13: Asia Pacific Therapeutic Albumin Market Revenue (USD billion) Forecast, by Source, 2019-2032
  • Table 14: Asia Pacific Therapeutic Albumin Market Revenue (USD billion) Forecast, by Indication, 2019-2032
  • Table 15: Asia Pacific Therapeutic Albumin Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 16: Asia Pacific Therapeutic Albumin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 17: Latin America Therapeutic Albumin Market Revenue (USD billion) Forecast, by Source, 2019-2032
  • Table 18: Latin America Therapeutic Albumin Market Revenue (USD billion) Forecast, by Indication, 2019-2032
  • Table 19: Latin America Therapeutic Albumin Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 20: Latin America Therapeutic Albumin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 21: Middle East & Africa Therapeutic Albumin Market Revenue (USD billion) Forecast, by Source, 2019-2032
  • Table 22: Middle East & Africa Therapeutic Albumin Market Revenue (USD billion) Forecast, by Indication, 2019-2032
  • Table 23: Middle East & Africa Therapeutic Albumin Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 24: Middle East & Africa Therapeutic Albumin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Therapeutic Albumin Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Therapeutic Albumin Market Value Share (%), by Source, 2024 & 2032
  • Figure 3: Global Therapeutic Albumin Market Value Share (%), by Indication, 2024 & 2032
  • Figure 4: Global Therapeutic Albumin Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 5: Global Therapeutic Albumin Market Value Share (%), by Region, 2024 & 2032
  • Figure 6: North America Therapeutic Albumin Market Value (USD billion), by Source, 2024 & 2032
  • Figure 7: North America Therapeutic Albumin Market Value Share (%), by Source, 2024
  • Figure 8: North America Therapeutic Albumin Market Value (USD billion), by Indication, 2024 & 2032
  • Figure 9: North America Therapeutic Albumin Market Value Share (%), by Indication, 2024
  • Figure 10: North America Therapeutic Albumin Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 11: North America Therapeutic Albumin Market Value Share (%), by Distribution Channel, 2024
  • Figure 12: North America Therapeutic Albumin Market Value (USD billion), By Country, 2024 & 2032
  • Figure 13: North America Therapeutic Albumin Market Value Share (%), By Country, 2024
  • Figure 14: Europe Therapeutic Albumin Market Value (USD billion), by Source, 2024 & 2032
  • Figure 15: Europe Therapeutic Albumin Market Value Share (%), by Source, 2024
  • Figure 16: Europe Therapeutic Albumin Market Value (USD billion), by Indication, 2024 & 2032
  • Figure 17: Europe Therapeutic Albumin Market Value Share (%), by Indication, 2024
  • Figure 18: Europe Therapeutic Albumin Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 19: Europe Therapeutic Albumin Market Value Share (%), by Distribution Channel, 2024
  • Figure 20: Europe Therapeutic Albumin Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 21: Europe Therapeutic Albumin Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 22: Asia Pacific Therapeutic Albumin Market Value (USD billion), by Source, 2024 & 2032
  • Figure 23: Asia Pacific Therapeutic Albumin Market Value Share (%), by Source, 2024
  • Figure 24: Asia Pacific Therapeutic Albumin Market Value (USD billion), by Indication, 2024 & 2032
  • Figure 25: Asia Pacific Therapeutic Albumin Market Value Share (%), by Indication, 2024
  • Figure 26: Asia Pacific Therapeutic Albumin Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 27: Asia Pacific Therapeutic Albumin Market Value Share (%), by Distribution Channel, 2024
  • Figure 28: Asia Pacific Therapeutic Albumin Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 29: Asia Pacific Therapeutic Albumin Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 30: Latin America Therapeutic Albumin Market Value (USD billion), by Source, 2024 & 2032
  • Figure 31: Latin America Therapeutic Albumin Market Value Share (%), by Source, 2024
  • Figure 32: Latin America Therapeutic Albumin Market Value (USD billion), by Indication, 2024 & 2032
  • Figure 33: Latin America Therapeutic Albumin Market Value Share (%), by Indication, 2024
  • Figure 34: Latin America Therapeutic Albumin Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 35: Latin America Therapeutic Albumin Market Value Share (%), by Distribution Channel, 2024
  • Figure 36: Latin America Therapeutic Albumin Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 37: Latin America Therapeutic Albumin Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 38: Middle East & Africa Therapeutic Albumin Market Value (USD billion), by Source, 2024 & 2032
  • Figure 39: Middle East & Africa Therapeutic Albumin Market Value Share (%), by Source, 2024
  • Figure 40: Middle East & Africa Therapeutic Albumin Market Value (USD billion), by Indication, 2024 & 2032
  • Figure 41: Middle East & Africa Therapeutic Albumin Market Value Share (%), by Indication, 2024
  • Figure 42: Middle East & Africa Therapeutic Albumin Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 43: Middle East & Africa Therapeutic Albumin Market Value Share (%), by Distribution Channel, 2024
  • Figure 44: Middle East & Africa Therapeutic Albumin Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 45: Middle East & Africa Therapeutic Albumin Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 46: Global Therapeutic Albumin Market Share (%), By Company, 2024